Subject index

(Numbers cited are abstract numbers)

A
- α-Galactosylceramide 656
- ABVD therapy 241, 244, 247, 249, 371, 555, 591, 600
- ABVD/OPP therapy 555
- Activated cytotoxic T-lymphocytes 91
- Activated T-cells 175
- Acute haematological toxicity 248
- Acute lymphoblastic leukemia 348
- ACV B 194, 427
- Adjuvant therapy 259, 384
- Adnexal involvement 492
- Adriamycin 382
- Adult Hodgkin’s disease 583
- Adult lymphoblastic lymphoma 63
- Advanced CLL 225
- Advanced diffuse large cell lymphoma 189
- Advanced high grade non-Hodgkin’s lymphoma 610
- Advanced Hodgkin’s disease 59, 61, 244, 245, 248, 560, 561, 586, 592
- Advanced indolent lymphoma 476
- Advanced low grade non-Hodgkin’s lymphoma 449, 459
- Advanced non-Hodgkin’s lymphoma 492, 653
- Advanced stage aggressive lymphoma 374
- Advanced stage diffuse large cell lymphoma 181, 425
- Advanced stage Hodgkin’s disease 555, 576, 577
- Advanced stage low grade lymphoma 219
- Age-related treatment 243, 253, 397
- Aggressive chemotherapy 392
- Aggressive head and neck non-Hodgkin’s lymphoma 386
- Aggressive intermediate high grade non-Hodgkin’s lymphoma 629
- Aggressive localized lymphoma 184
- Aggressive lymphoma 265, 374, 382, 402, 403, 416
- Aggressive mantle cell lymphoma 191
- Agricultural exposure 47
- ALK expression 129
- ALK lymphomas 89
- ALK oncogene expression 118
- Allelic imbalance 155
- Allogeneic bone marrow transplantation 111, 112
- Allogeneic transplantation 110
- Allografting 261
- All-trans retinoic acid 359
- Allotype therapy 79
- Alterations in DNA sequences 145
- Alternating MOPP/ABVD chemotherapy 244
- Anaplastic large cell lymphoma 80, 82, 90, 118, 129, 174, 346, 377, 407, 430, 530, 654
- Angiogenic growth factors 169
- Angio-immunoblastic T-cell lymphoma 130
- Angiolymphoid hyperplasia 93
- Animals 117
- Antibody levels 117
- Anti-CD20 antibody 568, 622
- Anti-CD20 antibody IDEC C2B8 11, 212, 658
- Anti-CD20 monoclonal antibody therapy 210, 224, 658
- Anti-CD25 565
- Anti-CD30 immunotoxin 106, 655
- Anti-Helicobacter therapy 70
- Anti-Helicobacter pylori treatment 229
- Antiproliferative effects 141
- Antisense oligonucleotide therapy 22, 113
- Antiviral therapy 38, 646
- Antitranscyline containing regimen 473
- Apoptosis 50, 58, 167, 366, 477, 478, 358
- Apoptosis-related proteins 326
- Apoptotic effects 141
- Arabinose 609
- Ara-C 396, 635
- Argentina 120
- ASCT 629
- Asymmetric collimation 282
- Ataxia-teleangiectasia 439
- ATM deletion 162
- ATM gene 20
- ATM heterozygosity 243
- Attained age 243
- Autografting 256, 261, 617
- Autoimmune diseases 165
- Autoimmune hemolytic anemia 322, 508
- Autoimmunity 365
- Autologous blood stem cell transplantation 597
- Autologous bone marrow transplantation 225
- Autologous haemopoietic cell transplantation 610
- Autologous haemopoietic progenitor cell support 260
- Autologous lymphocytes 100
- Autologous peripheral blood progenitor cell transplantation 274
- Autologous peripheral blood stem cell transplantation 600, 607, 641
- Autologous peripheral stem cell transplantation 42, 634
- Autologous stem cell support 62, 638
- Autologous transplantation 608, 620, 639
- Autotransplant 238, 603
- AZA anthracenedione 653

B
- β-integrin expression 161
- B-7 molecules 351
- BBR 277 653
- BCAVI 592
- B-cell chronic disorders 160, 351
- B-cell chronic lymphocytic leukemia 157, 224, 341, 456, 461, 478
- B-cell cutaneous lymphoma 55

183
B-cell differentiation 175
B-cell diffuse intermediate lymphoma 383
B-cell diffuse large-cell lymphoma 88, 168
B-cell lymphoma 17, 19, 76, 84, 136, 247, 666
B-cell lymphoproliferative disorders 304, 316
B-cell malignant lymphoproliferative disorders 471
B-cell neoplasms 58
B-cell non-Hodgkin's lymphoma 137, 162, 256, 288, 338, 363
B-cell purged autotransplantation 604
B-cell signalling complex 6
B-cellular chronic lymphoid leukemia 321
B-chronic lymphocytic leukemia 332, 367
BCL-2 expression 167, 168, 247, 315, 343, 345, 359
BCL-2 gene message 22
BCL-2/IgH rearrangements 214, 369
BCL-2 insertion 23
BCL-2 oncogene 208
BCL-2 protein 291, 297
BCL-6 30
BCL-6 gene hypermutations 135
BCL-6 mutations 345, 349, 369
BCL-6 proto-oncogene 337
BCL-10 gene abnormalities 19
BCNU 396, 635
BCR-induced death 31
BEACOPP chemotherapy 61, 576, 577
Beam autotransplant 237
Bendamustine 447, 452, 453, 458, 478, 479
BIK/NBK-1 167
Bilateral threphine biopsy 279
Biologic features 158
Biological markers 255
Biological prognostic factors 36, 163
BL60 cells 31
Bleomycin 245, 589
B-lineage chronic lymphoid malignancies 608
Blood cell transplantation 112
B lymphocyte-specific leukemia 350
B lymphoproliferative disorders 171
Body composition
Bone marrow particles 4, 295
Bone marrow transplantation 111, 112, 200
Bone mineral density 246
BOP 449
Breakpoint analysis 148
Breast cancer 243, 261
Brief chemotherapy 180
BuCyVP16 644
Bulky disease 244
Bulky Hodgkin's disease 560
Bulky mediastinal Hodgkin's disease 571
Burkitt's lymphoma 77, 120, 272, 370
Burkitt's lymphoma cell 366
Burkitt-like lymphoma 77
Busulfan 597
BVAM therapy 491
BW5147 656
C
CAMBO-VIP 374
Carboplatin 240
Cardiac function assessment 574
Cardiak toxicity 636
Caspase activation 136
Caspase-8 mutations 153
Castleman's disease 142, 670
CC3 expression 152
CCND1 171
CD4-lymphopenia 445
CD8-positive T-cell phenotype 94
CD10 expression 543
CD19+ selection 608
CD20 antibody 609
CD20 expression 104, 222
CD23 466
CD23 positivity 456
CD25a cell cycle 166
CD25b2 cell cycle 166
CD30+ 407
CD30 interaction 566
CD30 ligand 566
CD30 receptor 106, 152, 164, 174
CD30 negative B-lymphocytes 172
CD34+ blood stem cell transplantation 622
CD34+ cells 214, 609
CD34+ selection 608
CD40 transgenic mice 364
CD40L expression 568
CD43 expression 316, 543
CD44 expression 286
CD56 lymphoma 125, 190, 300
CD75 expression 543
CD79b expression 316
CD81 6
CD95(FAS)-expression 165
CDKN2 deletion 333
CDR3-PCR 338
Celiac disease 132
Cell apoptosis 332
Cell compartments 214
Cell death 367
Cell proliferation 332
Cell surface antigens 139
CENP-F expression 355
Central lymphatic irradiation 208
Central nervous system infiltration 419
Central nervous system relapse 43
Centroblasts 28
Centrocytes 28
Centrofacial non-Hodgkin's lymphoma 533
CEOP 193
Cerebral large cell non-Hodgkin's lymphoma 415
CEVOP-B 399
Chemo-radiotherapy 391, 422, 440, 483, 484, 536, 538
Chemoresistant diffuse large B-cell lymphoma 277
Chemoresistant diffuse large B-cell lymphoma 277
Chemosensitive patients 131
Chemotherapy intensification 108
Childhood acute lymphoblastic leukemia 441
Childhood advanced Hodgkin’s disease 443
Childhood advanced-stage T-cell lymphoblastic lymphoma 441
Childhood anaplastic large cell lymphoma 81, 83, 206
Childhood B-cell lymphoma 205, 431, 435
Childhood B-cell lymphoma 444
Childhood gastric B-cell lymphoma 436
Childhood HIV infection 437
Childhood Hodgkin’s disease 73-75, 440
Childhood intestinal non-Hodgkin’s lymphoma 434
Childhood large cell lymphoma 438
Childhood lymphoblastic lymphoma 78, 79, 202
Childhood lymphoma 442
Childhood Ki6 ALCL
Childhood malignancies 433
Childhood mediastinal large B-cell lymphoma 203
Childhood mediastinal non-Hodgkin’s lymphoma 432
Childhood non-Hodgkin lymphoma 204
Childhood small non-cleaved cell lymphoma 438
Chimeric anti CD-20 monoclonal antibody 482
China 135
Chlorambucil 70, 228, 245
2-chloro-2-deoxyadenosine 471, 526, 659
CHLPPP/EVA hybrid regimen 59
CHOD 481
CHOP therapy 64, 179, 195, 196, 201, 266, 270, 274, 371, 380, 382, 389, 394, 418, 427, 600
CHOP-like therapy 198
Chromosomal breakage syndrome 204
Chromosomal imbalances 356
Chromosome 13 deletion 44
Chromosome aberrations 157, 172
Chromosome translocations 23, 29
Chronic B-cell leukemia 144, 226
Chronic gastritis 543
Chronic lymphenadenitis 368
Chronic lymphocytic leukemia 72, 100, 111, 139, 222, 227, 228, 352, 353, 360, 454, 457, 464, 466, 471, 479
Chronic lymphoproliferative disorders 475
CHMnp/BV 66
Circulating T-cells 165, 212, 218
Cisplatin 375, 378, 470, 663
Cldarabine 445, 455, 471, 526, 659
Classical Hodgkin’s disease 5, 172
Clinical evaluation 394
Clinical features 158, 235
Clinical research 236
Clonal loss of heterogeneity 138
Clonally expanded T lymphocytes 361, 544
CML cells 141
CNOP therapy 193, 196
CNS involvement 329, 491, 530
CNS prophylaxis 410
CNS relapse 420
CTCL diagnosis 311
COA regimen 451
Coeolic disease 529
Collection efficiency 609
Combined modality therapy 251, 384
Comparative genomic hybridization 10, 145, 154
Complete remission 624, 640
Computer tomography 318, 371
Conformal radiotherapy 285
Consolidative treatment 265, 640
Continuous infusional chemotherapy 388
COP 449
COPA regimen 181
Corticosteroid-resistant T-lymphoma cells 167
Cost-effectiveness 620
ICR 272
CT scans 51, 314
CTL responses 170
Cure probability 254, 623
Cutaneous B-cell lymphoma 486
Cutaneous involvement 296
Cutaneous lymphoma 14, 54, 55
Cutaneous T-cell lymphoma 27, 94, 147, 152, 515
CVP chemotherapy 217, 220
CVPP 563
Cyclin DI 171
Cyclin dependent kinase 6 21
Cyclin E expression 355
Cyclophosphamide 22, 219, 223, 228, 382, 414, 424, 429, 461, 462, 471, 480, 563, 597, 612, 636, 641, 642
Cytarabine 375
Cytogenetic aberrations 404
Cytogenetic analysis 128, 142, 154, 342, 344
Cytokine profiles 32, 569, 588, 613
Cytokine-release syndrome 224
Cytogenetic characterisation 442
Cytoreduction 240, 469
Cytosine 609
Cytotoxic chemotherapy 246, 461
Cytotoxic proteins 514
CXCR3 160

D
Daunoxome 429
Dermatology 56
Dexa-BEAM 621, 635
Dexa-BID 479
Dexamethasone 211, 378, 396, 635
DHAP treatment 270
Diagnosis of lymphoma 279
Diethylmorphone 105
Diffuse large B-cell lymphoma 64, 88, 135, 151, 156, 163, 176, 180, 263, 291, 315, 317, 345, 404
Diffuse large cell lymphoma 35, 180, 183, 199, 200, 277, 289, 368, 417, 423, 427, 596, 620
Diffuse large cell non-Hodgkin’s lymphoma 409
DNA amplifications 356
Dose-escalated chemotherapy 267
Dose-intensified chlorambucil 228
Dose-intensity 12, 397, 427
Doxorubicin 223, 245, 359, 402, 657
Double autotransplant 265

185
Drug-induced cell death 367
Drug-induced apoptosis 167
Drug-resistant chronic lymphocytic leukemia 360

E
Early death 194
Early stage Hodgkin’s disease 249
Early stage primary extranodal lymphoma 540
EBV-negative PEL 522
EBV-related lymphoproliferative disorders 664
EBVP/MV therapy 589
ECHOP-B regimen 383
Economic G-CSF-support 394
Egypt 372, 373, 380, 434
Elevated antibody levels 118
EMP-salvage therapy 668
Endostatin 169
Engraftment 613
Enteropathy associated T-cell lymphoma 505
Enteropathy-type intestinal T-cell lymphoma 235
Environmental risk factors 308
EORTC classification 53
Eosinophilia 93, 134, 578
Eotaxin receptors 152
EpiADM 399
Epidemiology 46
Epirubicin 381, 414, 424, 454, 589, 594, 636
Epithelioid granulomas 281
Epitopes 170
EPOCH therapy 179
Epstein–Barr virus 2, 3, 5, 38, 117, 120, 120a, 348, 569, 585, 646
Eradication 230
Etiology of lymphoma 308
Etoposide 240, 245, 378, 381, 396, 400, 414, 452, 470, 589, 594, 612, 635, 642
Event-free survival 614
EVEP therapy 572
Exhaust 117
Extended field radiation 250, 282, 572
Extra biopsy specimens 304
Extranodal DLBCL 135
Extranodal Hodgkin’s lymphoma 237
Extranodal lymphocytic infiltrates 365
Extranodal lymphoma 236
Extranodal non-Hodgkin’s lymphoma 153, 237

F
FADD expression 136
Failure free survival 69, 247
Failure patterns 213, 234
Familial PMLCL 665
Family history 47
FAS 300
FAS-ligand 300
FAS-mediated cell death 367
FAS-mediated apoptosis 136
FAS mutations 153
18 FDG-pet 51
FDG-PET 122, 299
Feasibility 256, 576, 618
FGFR3 354
Fiber fish 343
Field irradiation 60
Fibroblasts 134
Field radiation 250
Fine needle 294
First line treatment 42, 205, 271, 629
FISH analysis 144, 157
Flavopiridol 141
Flow cytometry 304, 310
Fludarabine 211, 217, 219–221, 223, 375, 454, 457, 459, 462, 476, 480, 481, 508
Fludarabine combination therapy 227, 228, 461, 463, 474
Fludarabine phosphate 652
Fluorescence in situ hybridization 154
F-MACHOP 416, 629
Follicle centre cell lymphoma 176
Follicular dendritic cell like cell line 328
Follicular lymphoma cell line 328
Follicular mycosis fungoides 542
Follicular non-Hodgkin’s lymphoma 207, 319, 460, 605
Foscarnet 646
Framework derived sequences 170
France 192, 205, 298, 421
Front line chemotherapy 237, 266, 614, 641
Front line patients 227
Functional expression 159

G
Gallium scan 131, 312
Gallium-67 scintigraphy 314, 318
Gastric B-cell lymphoma 436
Gastric lymphoma 155, 231, 232, 233, 506, 545
Gastric MALT lymphoma 1, 229, 524, 527
Gastric non-Hodgkin’s lymphoma 535
Gastritis 165
Gastroenteropathy 494
Gastrointestinal involvement 191
Gastrointestinal malignancies 253
Gastrointestinal non-Hodgkin’s lymphoma 541, 547
G-CSF 427, 627, 641
Genescan analysis 338
Genetic imbalances 150
Gene therapy 114
Genotyping 146
Germany 228, 402
Germinal center development 28, 30, 31
Graft-versus-malignancy 110, 593
Granulomatous slack skin 493
Growth fraction 294
H

H-RS cells 154
Haematological malignancies 116
Haematological toxicity 248
Hairy cell leukemia 117
Harvest 108, 627
Harvest purity 613
Head and neck cancer 287, 540
Helicobacter pylori infection 230, 524
Hematological malignancies 325
Hematological neoplasia 261
Hematopoietic cells rescue 268
Hematotoxicity 186
Hemopathology biopsies 310
Hepatosplenic Yγδ-non-Hodgkin’s disease 517
Hepatic toxicity 320
Hepatitis B virus infection 288, 630
Hepatitis C virus infection 6, 121, 288, 320, 630
Hepatitis G virus 358
Hepatosplenic γδ T-cell lymphoma 92, 124
Heterozygosity 138, 156
HHV-8 genes 4, 522
High-dose sequential chemotherapy 273
High grade B-cell gastric lymphoma 230, 507
High grade B-cell lymphoma 658
High grade B lymphoblastic lymphoma 437
High grade lymphoma 371
High grade malignant non-Hodgkin lymphoma 401, 405
High grade primary gastrointestinal B-cell lymphoma 173
High risk diffuse large cell lymphoma 641
High risk follicular non-Hodgkin’s lymphoma 644
High risk lymphoma 603
High risk malignant non-Hodgkin’s lymphoma 640
High risk post-transplant lymphoproliferative disorders 647
High tumor burden 611
Histological progression 210
Histological transformation 216
Histomorphological analyses 306
Histopathological features 232
HIV 12-14, 322, 133, 415
HIV-associated non-Hodgkin’s lymphoma 105, 197
HIV-negative patients 536
HIV-negative PEL 522
HLA Class I expression 156
HLA Class II expression 156
HLA phenotypes 550
Hodgkin cells 134, 138, 247
Hodgkin-derived cell line 566
Hodgkin-like B-cell lymphoma 252
Hodgkin’s disease 33, 60, 106, 122, 154, 238, 239, 241-245, 247-255, 305, 323, 349-592, 616, 626
HRBCL 84
HTLV-I carrier 669
Human lymphoma cells 362
Hybrid-NOU therapy 561
Hyperfractionated radiotherapy 42
Hypersplenism 673

I

Idarubicin 221, 402, 426, 476, 632, 640
IDEC anti-CD20 antibody 648
IDEC-C28B 482
IDEC-Y2B8 215
Ifosfamide 240, 378, 381, 594
IgH genes 363
IgH rearrangements 23, 345, 369
IL-1 concentrations 340
IL-2 receptor measurement 373, 474
IL-10 concentrations 323, 325
IL-4 concentrations 325
IL-6 concentrations 340
IL-6A 349
Imaging algorithm 489
Immunoblastic lymphoma 88
Immunoblastic non-Hodgkin’s lymphoma 43
Immune competent patients 510
Immune compromised hosts 329, 330
Immunogenetic analysis 151
Immunoglobulin 170, 24
Immunohistochemical analysis 569
Immunohistological analyses 306
Immunologic expression 289
Immunophenotypic changes 210
Immunophenotypic subclones 341
Immunosuppressed patients 662, 664
Immunotherapy 32, 101
Immunotoxins 264
India 120
Induction therapy 212, 239
INF-γ concentrations 324
Infection rate 659
Infectious risk factors 308, 643
Intensive CHOP-therapy 394
Intensive therapy 188, 191, 268, 409, 631
Interferon α 218, 222, 469
Interferon α2b 188
Interferon-γ 104
Interleukin-2 445
Interleukin production 324
Intermediate-dose sequential chemotherapy 189
Intermediate grade lymphoma 371
Intermediate grade non-Hodgkin’s lymphoma 43, 193, 195, 201, 389, 397, 400, 413, 422, 428
Intermediate stage Hodgkin’s disease 230
Intermediate risk diffuse large cell lymphoma 641
Intermediate risk non-Hodgkin’s lymphoma 625
International Prognostic Index 67, 190, 231, 255, 393, 448, 468, 586
Interphase 343
Intestinal T-cell lymphoma 235
Intracranial heterogeneity 151
Intramammary lymph node 276
Intramammary lymphoma 276
Intraocular lymphoma 268
In vitro exposure to interferon 222

187
In vivo purging therapy 259
Involved-field radiotherapy 242
Iodine-131 anti-B1 antibody 99, 448
IPi 427
IPi high risk therapy 266
IPi score 617
Irradiation 41
Israel 506
Italy 119, 183, 207, 271

J
Japan 115

K
Kaposi sarcoma 322, 503
Kaposi sarcoma Herpes virus 503
Ki-1(CD30) leukemia 667
Ki-3(SCFV)-ETA 106
Ki-67 expression 140, 294, 567
Ki-67 nuclear proliferative antigen 291
Kiel classification 317
K-ras gene point mutations 368
Kuwait 562
Kyrgyzstan 432

L
Langerhans cell histiocytosis 552
Large cell anaplastic lymphoma 650
Large cell lymphoma 264, 420
Large T-cell transformation 499
Latent membrane protein 1 120a
LDH 668
Lenograstim 595
Leukemia 76, 114, 206
Leukemic bouts 326
Leukemic lymphocytosis 465
Leukopenia diagnosis 549
Liposomal vincristine 107
Local control 391
Localized aggressive non-Hodgkin’s lymphoma 115
Localized Hodgkin’s disease 251
Localized primary gastric diffuse large B-cell lymphoma 231
Locoregional high-dose radiotherapy 528
Lomustine 419
Long distance PCR 370
Long term disease control 528
Long term outcome 273, 292, 407
Long term side effects 250
Long term survival 671
Low grade B-cell lymphoma 148, 658
Low grade follicular lymphoma 257
Low grade gastric B-cell lymphoma 165
Low grade gastric lymphoma 70
Low grade gastric MALT lymphoma 500
Low grade lymphoma 111, 604, 609
Low grade malignant lymphoma 451
Low grade non-Hodgkin’s lymphoma 68, 100, 217, 221, 445, 446, 447, 450, 452, 455, 458, 460, 463, 468, 471, 474, 480
Low grade primary gastrointestinal B-cell lymphoma 173

Low-intermediate risk aggressive lymphoma 187
Lung injury 571
Lyme disease Borrelia 485
Lymphadenopathy 290
Lymph node involvement 493, 578
Lymphoblastic lymphoma 272
Lymphoblastic lymphoma relapses 202
Lymphocyte predominance Hodgkin’s disease 150
Lymphoid malignancies 260
Lymphoid microenvironment 324
Lymphoid tumor cells 159
Lymphoma among siblings 303
Lymphoma classification 15, 16
Lymphoma implants growth patterns 330
Lymphoma biomarkers 350
Lymphomagenesis 2
Lymphoma residual masses 299
Lymphoproliferative diseases 143, 322, 358, 365, 662

M
MACOP-B 201, 641
Macrophages 105
Magnetic resonance 314, 318
Male reproductive potential 575
Malignant B cells 160
Malignant lymphoma 50, 133, 275, 284, 355, 516, 621
MALT histology 545
MALT lymphoma 18, 488, 496, 500, 507, 524, 527, 531, 543, 547
Maltoma’s malignancy 546
Management of lymphoma 127, 235, 486, 540
Manganese superoxide dismutase levels 433
Marginal zone B-cell lymphoma 128, 335
Marrow flow cytometry 311
Massive bone marrow involvement 599
Mast cells 566
Mature B-cell lymphoma 76
M-CHEP 459
MDR-1 protein expression 297
Mdm2 protein status 585
Median nerve 537
Mediastinal fine-needle aspiration biopsy 293, 294
Mediastinal Hodgkin’s lymphoma 131
Mediastinal large B-cell lymphoma 203, 624
Mediastinal large cell lymphoma 580
Mediastinal lymphoma 318, 387
Mediastinal non-Hodgkin’s lymphoma 432
Mediastinal T-cell lymphoblastic lymphoma 410
Mediastinum 283
MegaCEOP 424
Melphalan 396, 453, 632, 635, 640
MEMID 198
Metalloproteinase overexpression 329
Metastatic breast cancer 261
Methotrexate 41, 378, 589
Mexico 533–535
MIB-1 87
Microdissected cells 527
Relapsed low grade non-Hodgkin's disease 479, 481
Relapsed lymphoma 612
Relapsed lymphoma residual masses 299, 597
Relapsed patients 227
Relapsed primary central nervous system lymphoma 268
Relapsing lymphoma 188, 375, 381
Remission 513, 527
Remission duration 659
Remission in Hodgkin’s disease 239
Reovirus induced cell death 331
Reproducibility of response 405
Residual diseases 244
Residual masses 51
Resistant aggressive non-Hodgkin’s lymphoma 637
Resistant B-prolymphocytic leukemia 467
Resistant chronic lymphocytic leukemia 462
Resistant hematological neoplasia 261
Resistant lymphoma 612
Resistant non-Hodgkin’s lymphoma 396
Response criteria 660
Response duration 209, 427
Restaging 131
Retinoblastoma protein 585
Retinoids 52, 664
Retropertioneal 283
Retrospective survival analysis 545
Revised European–American lymphoma classification 280, 292
Richter’s syndrome 352, 457
Richter’s transformation 464
Risk-adapted sequential combination chemotherapy 601
Risk assessment 183
Rituximab 613, 633
Rituximab 11, 101, 102, 103, 104, 195, 210, 212, 224, 256, 259, 460, 465, 467, 472, 482, 609, 622, 648, 658, 661, 662
RT + ASCT 629
Russia 229, 550
S
Salvage therapy 270, 375, 458, 642, 668
Sandwich delivering of radiotherapy 571
sCD30 concentrations 323
Scid mice 22, 26, 167
Sclerosis 203
Scoring systems 226
Secondary acute myelogenous leukemia 260
Secondary cutaneous CD30-positive lymphoproliferative disorders 126
Secondary non-Hodgkin’s lymphoma 406
Second line therapy 378
Second malignancies 582
Secreted eotaxin 134
Selection bias 243
Sequential FISH analysis 144
Sequential therapy 601, 602, 607, 614, 617, 618, 623, 632, 638
Serology 485
Serum B-2 microglobulin 190
Serum CA-125 levels 305
Serum ferritin 275
Serum IL-10 373
Serum levels 158, 588
Serum soluble interleukin-2 receptor levels 336
Sézary syndrome 147, 490
SFOP LMT 89 202
Siblings 303
Single-cell PCR 361
Skin 544
Skin electron irradiation 548
Skin node involvement 493
Slowly progressive lymphadenopathy 290
Small cell lymphoma 353
Small lymphocytic lymphoma 456, 598
Small plaque psoriasis 544
Solid allograft recipients 649
Solid organ transplantation 645
Solitary plasmacytoma 497
Soluble CD30 164
Soluble ICAM-1 158
Soluble IL-2 373
Soluble VCAM-1 158
Spain 264, 284
Splenectomy 475, 508
Splenectomy irradiation 673
Splenectomy 21
Splenectomy with vitilous lymphocytes 121, 301
Splenectomy marginal zone lymphoma 301
Splenectomy rupture 674
Stage of lymphoma 295
Standard chemotherapy 66
Standard staging procedures 122
Stanford V regimen 560
Stem cell autotransplantation 637
Stem cell mobilization 613
Stem cell rescue 635
Stem cell support 267, 615, 633
Stem cell transplant 191
Stomach lymphoma 488, 504
Subcutaneous NK/T cell lymphoma 502
Subtle Leydig cell dysfunction 246
Surgical therapy 545
Survival 85, 201, 209, 231, 391, 420, 427, 446, 545, 637, 668
Survival selection 366
Syndecan-1/CDS18 362
Systemic human cell lymphoma 22
Systemic large cell non-Hodgkin’s lymphoma 415

T
T(4;14) concentration 354
t(8;14)(q24;q32) translocation 370
T(11;18)(q21;q21) 18, 148
T(14;18) concentration 47, 212, 218, 342
t(14;18)(q32;q21) 208
T-cells 134
T-cell cutaneous lymphoma 52, 55, 56, 57
T-cell Hodgkin’s lymphoma 49
T-cell lymphoblastic lymphoma 79
T-cell lymphoma 92, 124, 327
T-cell non-Hodgkin's lymphoma 337
T-cell receptors 32
T-cell rich large B-cell lymphoma 302, 313, 435
T-lymphocyte proliferation 351
Tandem autologous stem cell transplantation 109
Tandem high-dose therapy 615
Tandem transplants 44, 261
TCL-1 oncogene expression 143
Telomerase activity 147
Testicular lymphoma 234, 518, 539
Thymic reactive hyperplasia 584
Thymidine kinase serum level 307
TNF-α serum levels 339
TNF receptor-associated factors 557
Topotecan 400
tolerability 199
Topoisomerase IIα expression 140
Total body irradiation 270
Toxicity 244, 273, 389, 425, 576, 591, 618
TP53 expression 315
TRAF2 557
TRAF3 557
TRAF5 557
TRAIL 159
Transformed variants of non-Hodgkin's lymphoma 357
Treatment outcome 233
Treatment planning 285
Treatment resistance 366
Trimetrexate 515
Trisomy 12 144, 341
TTP toxicity 623
Tumor dissemination 161
Tumor growth 167, 514
Tumor load 604
Tumor markers 327
Tumor necrosis 3
Tumor necrosis factor polymorphisms 149
Tumor size 497
Tumor suppressor genes 146
Two-colour flow cytfluorometry 321

U
Uganda 133
Unconjugated monoclonal antibody therapy 95
Unilateral biopsy 279
United Kingdom 236, 245, 504, 505, 554
Universal PCR 154
Up-front therapy 274, 399

V
Vβ phenotyp 327
Vaccines 95
VANDA protocol 202
V(D)J recombinase 26, 29
Venezuela 431
VEPEMB regimen 573
VH gene family utilization 347
Villous lymphocytes 508
Vinblastine 245, 563, 589
Vincristine 245, 382, 414, 429
Vincristine–adriamycin continuous infusion 395
Visceral involvement 82
VNCOP-B 65, 178
VP16 399

W
Waf-1 protein 567
Waldenstrom's macroglobulinaemia 223, 301
Waldeyer's ring lymphoma 484
Waldeyer's ring non-Hodgkin's lymphoma 483, 501
Whipple disease 290
WHO classification 86
Working formulation 280

Y
90yttrium 215